5 completed, 3 active not recruiting, 2 terminated, 1 recruiting. 13 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 5, Active not recruiting 3, Terminated 2, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 6 | Completed 3, Active not recruiting 2, Recruiting 1 |
Follow Recurrent Colorectal Carcinoma: new trials by email Literature Review of Recurrent Colorectal Carcinoma trials Research Report on Recurrent Colorectal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) Biopsy, Pembrolizumab, Therapeutic Autologous Dendritic Cells - Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma | Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2024-10-01 | 2024-09-26 | |
| Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer Aminolevulinic Acid, Biospecimen Collection, Computed Tomography - Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Roswell Park Cancer Institute | 21 | 2024-07-30 | 2026-10-15 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer Abemaciclib, Cetuximab, ERK1/2 Inhibitor LY3214996 - Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 46 | 2020-12-02 | 2026-10-05 |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer Cetuximab, Encorafenib, Nivolumab - BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 38 | 2019-06-14 | 2026-06-11 |
| Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia rhTPO, irinotecan, Raltitrexed - Recurrent Colorectal Carcinoma, Thrombopenia | Phase 2 | Unknown | Fudan University | 50 | 2019-02-01 | 2019-01-30 |
| Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver Celecoxib, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 19 | 2018-04-19 | 2022-03-02 |
| Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer Atezolizumab, Bevacizumab, Capecitabine - Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma | Phase 2 | Completed | Academic and Community Cancer Research United | 133 | 2017-07-07 | 2024-08-23 |
| Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery Chemotherapy, Laboratory Biomarker Analysis, Metastasectomy - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 2 | Terminated | M.D. Anderson Cancer Center | 29 | 2016-09-23 | 2026-02-17 |
| Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery Cetuximab, Laboratory Biomarker Analysis, Pembrolizumab - Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 45 | 2016-08-05 | 2022-10-06 |
| FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2016-02-16 | 2018-08-16 |
| Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas SGM-101 - Colon Cancer, Rectum Cancer | Phase 1 / Phase 2 | Completed | Surgimab | 75 | 2016-01-01 | 2019-07-18 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-10-26 |
| Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma Imprime PGG 2 mg/kg, Imprime PGG 4 mg/kg, Cetuximab - Recurrent Colorectal Carcinoma, Progressive Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | HiberCell, Inc. | 32 | 2007-10-01 | 2025-03-19 |
Colorectal Neoplasms (13) · Colonic Neoplasms (4) · Rectal Neoplasms (4) · Pancreatic Neoplasms (2) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Disease Progression (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Lymphoma (1)
Colonic Diseases (13) · Digestive System Diseases (13) · Digestive System Neoplasms (13) · Gastrointestinal Diseases (13) · Gastrointestinal Neoplasms (13) · Intestinal Diseases (13) · Intestinal Neoplasms (13) · Neoplasms by Site (13) · Rectal Diseases (13) · Neoplasms (12) · Disease Attributes (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2)
Cetuximab (4) · Irinotecan (3) · Biopsy (2) · Disulfides (2) · Immunoglobulin G (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Specimen Handling (2) · pembrolizumab (2) · 1-phenyl-3,3-dimethyltriazene (1) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 2C4 antibody (1) · AZD4547 (1) · Ado-Trastuzumab Emtansine (1) · Afatinib (1)
Roswell Park Cancer Institute (4) · M.D. Anderson Cancer Center (3) · Academic and Community Cancer Research United (1) · City of Hope Medical Center (1) · Fudan University (1) · HiberCell, Inc. (1) · National Cancer Institute (NCI) (1) · Surgimab (1)
United States (10) · Guam (1) · Netherlands (1) · Philippines (1) · Puerto Rico (1)
Alexander L Vahrmeijer, MD, PhD (1) · Anthony S Dakwar (1) · Christine M Parseghian, MD (1) · Christos Fountzilas (1) · Gerardo Cornelio, MD, FPCP/FPS (1) · Keith T Flaherty (1) · Ma. Belen Tamayo, MD (1) · Marwan Fakih (1) · Niharika Mettu (1) · Sarbajit Mukherjee (1) · Sarbajit Mukherjee, MD (1) · Van K Morris (1) · Yun S Chun (1) · Zhen Zhang, MD (1)
PMID 26586415, PMID 29361435, PMID 31960953, PMID 32416765, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 35179586, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40865033, PMID 41066729, PMID 41793309
P01CA234212 (1), P30CA015083 (1), P30CA016056 (1), R01CA187238 (1), U10CA180820 (1), U24CA196172 (1), UL1TR001412 (1)